Molecular Profile Detail

Request Content

Contact

Missing content? – Request curation!

Request curation for specific Genes, Variants, or PubMed publications.

Have questions, comments, or suggestions? - Let us know!

Email us at : ckbsupport@genomenon.com

Profile Name	EML4 - ALK ALK I1171N ALK L1198F
Gene Variant Detail	ALK I1171N (gain of function) ALK L1198F (gain of function) EML4 - ALK (gain of function)
Relevant Treatment Approaches

Filtering

Case insensitive filtering will display rows if any text in any cell matches the filter term
Use simple literal full or partial string matches
Separate multiple filter terms with a space. Any order may be used (i. e. a b c and c b a are equivalent )
Filtering will only apply to rows that are already loaded on the page. Filtering has no impact on query parameters.
Use quotes to match on a longer phrase with spaces (i.e. "mtor c1483f")

Sorting

Generally, the default sort order for tables is set to be first column ascending; however, specific tables may set a different default sort order.
Click on any column header arrows to sort by that column
Hold down the Shift key and click multiple columns to sort by more than one column. Be sure to set ascending or descending order for a given column before moving on to the next column.

Filter rows:

Showing 1 to 18 of 18 entries

Molecular Profile	Indication/Tumor Type	Response Type	Relevant Treatment Approaches	Therapy Name	Approval Status	Evidence Type	Efficacy Evidence	References
EML4 - ALK ALK I1171N ALK L1198F	Advanced Solid Tumor	conflicting		Crizotinib	Preclinical - Cell culture	Actionable	In a preclinical study, Xalkori (crizotinib) inhibited viability of transformed cells expressing EML4-ALK with ALK I1171N and ALK L1198F in culture (PMID: 33627640).	33627640
EML4 - ALK ALK I1171N ALK L1198F	Advanced Solid Tumor	resistant		Alectinib	Preclinical - Cell culture	Actionable	In a preclinical study, transformed cells expressing EML4-ALK with ALK I1171N and L1198F were resistant to treatment with Alecensa (alectinib) in culture (PMID: 33627640).	33627640
EML4 - ALK ALK I1171N ALK L1198F	Advanced Solid Tumor	resistant		Ceritinib	Preclinical - Cell culture	Actionable	In a preclinical study, transformed cells expressing EML4-ALK with ALK I1171N and L1198F were resistant to treatment with Zykadia (ceritinib) in culture (PMID: 33627640).	33627640
EML4 - ALK ALK I1171N ALK L1198F	Advanced Solid Tumor	resistant		Brigatinib	Preclinical - Cell culture	Actionable	In a preclinical study, transformed cells expressing EML4-ALK with ALK I1171N and L1198F demonstrated resistance to treatment with Alunbrig (brigatinib) in culture (PMID: 33627640).	33627640
EML4 - ALK ALK I1171N ALK L1198F	Advanced Solid Tumor	predicted - resistant		Entrectinib	Preclinical - Cell culture	Actionable	In a preclinical study, transformed cells expressing EML4-ALK with ALK I1171N and L1198F demonstrated resistance to treatment with Rozlytrek (entrectinib) in culture (PMID: 33627640).	33627640
EML4 - ALK ALK I1171N ALK L1198F	Advanced Solid Tumor	resistant		Lorlatinib	Preclinical - Cell culture	Actionable	In a preclinical study, transformed cells expressing EML4-ALK with ALK I1171N and L1198F were resistant to treatment with Lorbrena (lorlatinib) in culture (PMID: 33627640).	33627640
EML4 - ALK ALK I1171N ALK L1198F	Advanced Solid Tumor	sensitive		Gilteritinib	Preclinical - Cell culture	Actionable	In a preclinical study, Xospata (gilteritinib) inhibited viability of transformed cells expressing EML4-ALK with ALK I1171N and ALK L1198F in culture (PMID: 33627640).	33627640
EML4 - ALK ALK I1171N ALK L1198F	Advanced Solid Tumor	sensitive		TPX-0131	Preclinical - Cell culture	Actionable	In a preclinical study, TPX-0131 inhibited proliferation of transformed cells expressing ALK I1171N and ALK L1198F compound mutation in the context of EML4-ALK in culture (PMID: 34158340).	34158340
EML4 - ALK ALK I1171N ALK L1198F	Advanced Solid Tumor	conflicting		Crizotinib	Preclinical - Cell culture	Actionable	In a preclinical study, transformed cells expressing ALK I1171N and ALK L1198F compound mutation in the context of EML4-ALK were resistant to Xalkori (crizotinib) treatment in culture (PMID: 34158340).	34158340
EML4 - ALK ALK I1171N ALK L1198F	Advanced Solid Tumor	resistant		Alectinib	Preclinical - Cell culture	Actionable	In a preclinical study, transformed cells expressing ALK I1171N and ALK L1198F compound mutation in the context of EML4-ALK were resistant to Alecensa (alectinib) treatment in culture (PMID: 34158340).	34158340
EML4 - ALK ALK I1171N ALK L1198F	Advanced Solid Tumor	resistant		Brigatinib	Preclinical - Cell culture	Actionable	In a preclinical study, transformed cells expressing ALK I1171N and L1198F compound mutation in the context of EML4-ALK were resistant to Alunbrig (brigatinib) treatment in culture (PMID: 34158340).	34158340
EML4 - ALK ALK I1171N ALK L1198F	Advanced Solid Tumor	resistant		Ceritinib	Preclinical - Cell culture	Actionable	In a preclinical study, transformed cells expressing ALK I1171N and L1198F compound mutation in the context of EML4-ALK were resistant to Zykadia (ceritinib) treatment in culture (PMID: 34158340).	34158340
EML4 - ALK ALK I1171N ALK L1198F	Advanced Solid Tumor	resistant		Lorlatinib	Preclinical - Cell culture	Actionable	In a preclinical study, transformed cells expressing ALK I1171N and L1198F compound mutation in the context of EML4-ALK were resistant to Lorbrena (lorlatinib) treatment in culture (PMID: 34158340).	34158340
EML4 - ALK ALK I1171N ALK L1198F	Advanced Solid Tumor	conflicting		Crizotinib	Preclinical - Cell culture	Actionable	In a preclinical study, Xalkori (crizotinib) treatment inhibited viability of transformed cells expressing EML4-ALK with ALK I1171N and ALK L1198F in culture (PMID: 35726063).	35726063
EML4 - ALK ALK I1171N ALK L1198F	Advanced Solid Tumor	resistant		Ceritinib	Preclinical - Cell culture	Actionable	In a preclinical study, transformed cells expressing EML4-ALK with ALK I1171N and ALK L1198F were resistant to Zykadia (ceritinib) in culture (PMID: 35726063).	35726063
EML4 - ALK ALK I1171N ALK L1198F	Advanced Solid Tumor	resistant		Alectinib	Preclinical - Cell culture	Actionable	In a preclinical study, transformed cells expressing EML4-ALK with ALK I1171N and ALK L1198F were resistant to Alecensa (alectinib) in culture (PMID: 35726063).	35726063
EML4 - ALK ALK I1171N ALK L1198F	Advanced Solid Tumor	resistant		Lorlatinib	Preclinical - Cell culture	Actionable	In a preclinical study, transformed cells expressing EML4-ALK with ALK I1171N and ALK L1198F were resistant to Lorbrena (lorlatinib) in culture (PMID: 35726063).	35726063
EML4 - ALK ALK I1171N ALK L1198F	Advanced Solid Tumor	predicted - sensitive		NVL-655	Preclinical - Cell culture	Actionable	In a preclinical study, NVL-655 moderately inhibited viability of cells expressing EML4-ALK, ALK I1171N, and ALK L1198F in culture (PMID: 39269178).	39269178

Showing 1 to 18 of 18 entries

Filter rows: